Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Comparison of efficacy and safety of glargine insulin and metformin as first line drug of
patients insufficiently treated with lifestyle intervention. So far treatment also algorithm
with lifestyle and metformin has not been evaluated in patients with type 2 diabetes and
HbA1C greater or equal 7 % and lower than 8.1%.Besides HbA1C postprandial glucose excursion
and glycemic variability as determinants of oxidative stress will be measured by continuous
glucose measurement(CGM). Further more CGM will reveal risk of hypoglycemia at night. As
secondary objectives effect on endothelial function, renal function and biomarkers of low
great inflammation will be evaluated. So far only scarce information on face to face
comparison in ealy diabetes exists.